Nothing Special   »   [go: up one dir, main page]

Varicella (Chickenpox) Disease: Chananart Yuakyen: Icn

Download as pdf or txt
Download as pdf or txt
You are on page 1of 28

Varicella

(Chickenpox)
Disease
CHANANART YUAKYEN : ICN
Definition

• Varicella (Chicken pox) is a disease caused by the


varicella zoster virus; it causes fever and an itchy
rash
Infectious agent

• Varicella-zoster virus (VZV) is a DNA virus


of the herpes virus family.
•It causes two diseases:
• varicella (chickenpox), the primary infection,
• and herpes zoster (shingles), a secondary
infection due to a reactivation of latent varicella
infection in the dorsal root ganglia
Signs and Symptoms

• Symptoms include a skin rash of blister-like lesions,


covering the body but mostly concentrated in the face,
scalp and trunk. Most infected individuals experience
fever developing either just before or when the rash
appears. If a vaccinated individual is exposed they may
experience a milder illness with less severe rash and mild
or no fever.

dewdrops on a rose petal


Occurrence
• Worldwide.
• At lease 90% of the population has had chickenpox by age 15
• At lease 95% by young adulthood

• In temperate zones, chickenpox occurs most frequently in winter


and early spring.

• The epidemiology of varicella in tropical countries differs from


temperate climates, with a higher proportion of cases occurring
among adults.

• Herpes zoster occurrence has been described most commonly in


developed countries where Zoster occurs more commonly in
older people 50 years of age.
Occurrence

• Chickenpox typically infects children under the age of 10;


5-10 % of the population remains susceptible to the
disease in adulthood.
• Lifetime risk of reactivation as zoster/shingles is about 15-
20 % and can occur at any time, most often in the elderly
population.
Reservoir
•Humans
Mode of transmission

• Person-to-person by direct contact,


• Droplet or airborne spread of vesicle fluid,
• Secretion of the respiratory tract of chickenpox cases
• Vesicle fluid of patients with herpes zoster
• Indirectly through articles freshly soiled by discharges
from vesicle and mucous membranes of infected
people
Mode of transmission (cont.)

• Varicella in unvaccinated persons is one of the


most readily communicable of diseases,
especially in the early stages of the eruption,

• Secondary attack rates in susceptible household


contacts range from 61% to 100%

• Scabs from varicella lesion are not infective.


Mode of transmission (cont.)

• Herpes zoster has a lower rate of transmission:

• Data from a household study showed that 20%


of those who are varicella seronegative develop
varicella when they are in contact with persons
who have herpes zoster
Incubation period

• 10-21 days
• Commonly 14-16 days
• May be prolonged as long as 28 days after passive
immunization against varicella
• And may be shortened in the immunodeficient.
(8-21 days)
Period of communicability

• As long as 5 days,
• But usually 1-2 days before onset of rash,
• And continuing until all lesions are crusted
(usually about 5 days).
Period of communicability (cont.)

• Contagiousness may be prolonged in patients


with altered immunity.
• The secondary attack rate among susceptible
siblings is 60-100%.
• Patients with herpes zoster may be infectious for
a week after the appearance of vesiculopustula
lesion.
• Susceptible individuals should be considered
infectious for 10-21 days following exposure.
Contagiousness
all lesions
are crusted

1-2 days 5 days


Susceptibility
• Susceptibility to varicella is universal among
those not previously infected or vaccinated;
• Ordinarily a more severe disease of adults than of
children.

• Infection usually confers long immunity;


• Second attack are rate in immunocompetient persons
but have been documented ;
• Subclinical reinfection is common.
Susceptibility

• Viral infection remains latent;


• Disease may recur years later as herpes zoster.

• Herpes zoster occurs in about 15% of older adults,


and rearly in children.
Susceptibility
• Neanates whose mothers are not immune and
patients with leukemia may suffer severe,
• Prolonged or fetal chickenpox.

• Adults with cancer-especially of lymphoid tissue,


with or without steroid therapy-immunodeficint
patients and those on immunosuppressive
therapy may have an increased frequency of
severe herpes zoster, both localized and
dissaminated.
Methods of control

• Preventive measures.

• Control of patient, contacts and the immediate


environment.

• Epidemic measures.
Methods of control ; Preventive measures

• Protect high-risk individuals who cannot be


immunized
• e.g. non-immune neonates and the immunodeficient-
from exposure, by immunizing household or other
close contacts.
Methods of control ; Preventive measures

• A herpes zoster vaccine


• for older adults has been approved and recommended for
use in the USA for healthy persons aged 60 years or older.

• Varicella-zoster immune globulin (VZIG or VariZIG),


• prepared from the plasma of noemal blood donors with
high VZV antibody titer,
• effectively modifies or prevents disease if given within
96 hours after exposure.
Methods of control ;Control of patient, contacts
and the immediate environment.

• Isolation
• Exclude children from school, medical offices, emergency
rooms or public places until vesicles become dry and
crusted, usually after 5 days in non-immunized children
and 1-4 days with breakthrough varicella in immunized
children;
• Exclude infected adults from workplace and avoid contact
with susceptibles.

• In hospital, observe strict isolation, because


of the risk of varicella in susceptible
immunocompromised patients.
Methods of control ;Control of patient, contacts
and the immediate environment. (cont.)

• Quarantine.
• in places where susceptible children with known
recent exposure must remain for medicle reasons, the
risk of spread to steroid-treated or immunodeficient
patients may justify quarantine of known contacts for
at lease 10-21 days after exposure (up to 28 days if
VZIG was given).
Methods of control ;Control of patient, contacts
and the immediate environment. (cont.)

• Protection of contacts:
• Varicella vaccine is effective in preventing illness or
modifying severity if used within 3 days, and possibly
up to 5 days, of exposure; it is recommended for
susceptible persons following exposure to
varicella.
Methods of control ; Control of patient, contacts
and the immediate environment. (cont.)
• Protection of contacts: (cont.)
• VZIG
• Within 96 hours of exposure may prevent or modify
disease in susceptible close contacts of cases.
• It is available in several countries for high-risk persons
exposed to chickenpox, and indicated for newborns of
mothers who develop chickenpox within 5 days prior to
or 2 days after delivery.
• There is no assurance that administering VZIG to a
pregnant woman will prevent congenital malformations
in the fetus, but it may modifify varicella severity in the
pregnant woman.
Methods of control ; Control of patient, contacts
and the immediate environment. (cont.)

• Protection of contacts: (cont.)


• Antiviral drugs such as acyclovir
• appear useful in preventing or modifying varicella in
exposed in individuals if given within a week of
exposure. Most studied have been carried out in
immunocompromised children, with few data available
for healthy children.
• A dose of 8o mg/kg/day in 4 divided doses has been
used,
• But no regimen is as yet generally recommended for this
purpose.
Methods of control ; Control of patient, contacts
and the immediate environment. (cont.)

• Specific treatment:

• Antiviral therapy is moderately effective in treating


varicella and herpes zoster infections: acyclovir,
valacyclovir or famcyclovir are considered the agents
of choice for treatment or varicella…

You might also like